Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. QIAGEN N.V.
  6. News
  7. Summary
    QGEN   NL0012169213

QIAGEN N.V.

(QGEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

QIAGEN N : Disclosure according to Article 5 Section (1) and (6) of the EU Regulation 596/2014 and Article 2 Section (1) of the Delegated EU Regulation 2016/1052/ Share Repurchase

07/20/2021 | 05:08am EDT

QIAGEN N.V. ('Company') announces the start of the share repurchase program that was announced by an ad-hoc announcement on July 12, 2021.

In the time period between July 20, 2021, until September 17, 2021, at the latest and based on current prices, approximately 2.1 million common shares of the Company having a total purchase price of up to $100 million (or the equivalent Euro amount thereof, in each case without ancillary purchasing costs) shall be repurchased mainly on the electronic trading platform of the Frankfurt Stock Exchange (XETRA) and may also be repurchased on the trading platform of CBOE Europe and Turquoise Europe. The maximum purchase price per share (excluding ancillary purchase costs) will not exceed the average closing price for the last five trading days prior to the day of purchase on the electronic trading platform of the Frankfurt Stock Exchange by more than 10%.

The purpose of the share repurchase is to hold shares in treasury in order to satisfy obligations from employee share-based remuneration plans. The Managing Board of QIAGEN N.V., upon authorization of the Supervisory Board, is thus exercising the authorization by the Annual General Meeting on June 29, 2021.

The repurchase program will be carried out on behalf and account of QIAGEN N.V. through a financial institution commissioned by the Company. The financial institution will decide on the timing of the share purchase independently, without being influenced by the Company.

The share repurchase program will be implemented in accordance with the trading terms of Article 5 Section (1), (2) and (6) of the EU Regulation no 596/2014 and the Delegated EU Regulation no 2016/1052. In accordance with said EU Regulations, no purchase price may be paid that exceeds the price of the last independent trade or the highest current independent bid on the respective trading platform on which the repurchase is carried out. The higher of both values is decisive.

In addition, no more than 25% of the average daily volume of shares on the respective trading platform on which the repurchase is carried out may be acquired. The average daily volume of shares is based on the average daily volume traded on the respective trading platform over the twenty stock exchange trading days preceding the date of the purchase.

The share repurchase program may be suspended and resumed at any time, in line with applicable statutory regulations.

The transactions will be announced in a manner compliant with the requirements of Art. 2 Section (3) of the Delegated EU Regulation no 2016/1052 no later than on the seventh trading day following their conclusion.

In addition, QIAGEN N.V. will provide regular updates on the progress of the share repurchase program at www.qiagen.com.

Venlo, July 20, 2021

The Managing Board

###

Disclaimer

Qiagen NV published this content on 20 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 July 2021 09:07:03 UTC.


© Publicnow 2021
All news about QIAGEN N.V.
09/17QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
EQ
09/17QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
DJ
09/14QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
EQ
09/14QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
DJ
09/14QIAGEN N.V. : Release of a capital market information
DJ
09/10QIAGEN N : 3M, Qiagen to comply with Biden's COVID-19 vaccination, test mandate
RE
09/10QIAGEN N : supports White House COVID-19 vaccination, test mandate
RE
09/07QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
EQ
09/07QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
DJ
09/07QIAGEN N.V. : Release of a capital market information
DJ
More news
Analyst Recommendations on QIAGEN N.V.
More recommendations
Financials (USD)
Sales 2021 2 151 M - -
Net income 2021 448 M - -
Net Debt 2021 923 M - -
P/E ratio 2021 27,8x
Yield 2021 -
Capitalization 12 351 M 12 351 M -
EV / Sales 2021 6,17x
EV / Sales 2022 6,33x
Nbr of Employees 5 900
Free-Float 98,3%
Chart QIAGEN N.V.
Duration : Period :
QIAGEN N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends QIAGEN N.V.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 54,34 $
Average target price 55,88 $
Spread / Average Target 2,84%
EPS Revisions
Managers and Directors
Thierry Bernard Chief Executive Officer & Managing Director
Roland Sackers Chief Financial Officer & Managing Director
Lawrence A. Rosen Chairman-Supervisory Board
Barthold Piening Senior Vice President & Head-Global Operations
Metin Colpan Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
QIAGEN N.V.2.82%12 351
MODERNA, INC.311.65%173 588
LONZA GROUP AG32.35%60 074
IQVIA HOLDINGS INC.43.07%49 116
CELLTRION, INC.-23.26%31 904
SEAGEN INC.-10.81%28 420